euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces Q4 and preliminary full-year 2007 results:

First profitable year in company history - Vaccine against Japanese Encephalitis
fully on track towards all markets - Excellent progress
in product pipeline and strategic partnerships - focus on new vaccines
against hospital-acquired infections and improved Influenza vaccines (E)=

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

03.03.2008

First profitable year in Intercell´s history - Clear growth in revenues and
profitability expected for 2008

» EUR 5.0 m net profit and positive operating cash flow of EUR 41.7 m
» Revenues of EUR 53.3 m, an increase of 127.5 percent - driven by payments
from strategic alliances
» R&D costs of EUR 40.4 m enabled all programs to be progressed forward
at full speed in order to fully take advantage and create the maximum
possible value from the development programs and technology platforms
» Strong cash position with EUR 287.6 m - plus, unconditional EUR 40.0 m
payment already committed for 2008
» Clear revenue and profit growth expected in 2008 based on the approval of
the Japanese Encephalitis vaccine and on income from product and technology
partnerships
» Given this result and strategy, Intercell joined the ranks of the few
profitable biotechnology companies worldwide

Clear strategy to market for the first product - Intercell´s investigational
Japanese Encephalitis vaccine

» Market Authorization Application (MAA) in Europe and Biological License
Application (BLA) with the US Food and Drug Administration (FDA) submitted
in December 2007, and already excepted
» Licensure application to Australian Therapeutic Goods Administration (TGA)
submitted in February of 2008
» Intercell Biomedical Ltd. (Scotland) received Manufacturer´s License for
commercial manufacturing
» FDA pre-approval inspection of the facilities pre-scheduled for April of 2008
» Data from pediatric clinical trials in endemic countries expected within
the next weeks
» Intercell´s cooperation with the US Army, geared toward the long-term
supply of the JE-vaccine for the military, is progressing well -
contractual agreement expected latest upon FDA approval

Novartis alliance

» Phase I clinical trial for an improved seasonal Influenza vaccine
formulated with IC31® completed successfully - Intercell´s adjuvant IC31®
demonstrates very good safety and tolerability profile. Novartis will
continue clinical Phase I/II development of IC31® adjuvanted flu vaccines
in 2008
» Joint therapeutic vaccine program against HCV met primary endpoints in
Phase II - data confirms findings of the interim analysis from Q3 2007 -
statistically significant viral load reduction and excellent safety profile
- further clinical trials in co-development with Novartis to include IC31®
» Cooperation with Novartis is based on a major strategic partnership that
was signed in July of 2007

Hospital acquired-infections

» S. aureus vaccine - Merck & Co., Inc. has initiated Phase II clinical
development by the end of 2007. Intercell expects further extension of
clinical program into additional indications in early 2008
» Pseudomonas vaccine - preparations for start of clinical Phase II/III
trials in 2008 underway
» Pre-clinical candidates for further nosocomial vaccine and antibody product
targets including Klebsiella have been identified

Tuberculosis

» Further clinical trials started at the Department of Infectious Diseases
at the Leiden University Medical Center, Netherlands, within the new global
franchise to fight Tuberculosis
» Tuberculosis vaccine will be further developed in a collaboration between
Sanofi Pasteur and Statens Serum Institut (SSI) including Intercell´s
adjuvant IC31®, strongly supported by the Aeras Global Tuberculosis
Foundation and the EU

Technology platforms: IC31® & AIP®

» Pneumococcus vaccine candidate funded by PATH on course to entering
clinical Phase I trials in 2008
» Developmental programs and partnerships in the field of vaccines and
monoclonal antibodies for Group B Streptococcus and hospital-acquired
infections to be accelerated
» New partnerships for adjuvant IC31® and the definition of new vaccine
candidates from AIP® expected for 2008

Management Board

» The Management Board, with Gerd Zettlmeissl as Chief Executive Officer,
Werner Lanthaler as Chief Financial Officer, and Alexander von Gabain as
Chief Scientific Officer appointed for a further three-year term. Thomas
Lingelbach appointed as new member of the Management Board as Chief
Operating Officer.

EUR in thousands 3 months ended
Dec 31, Dec 31, Year ended

2007 2006 2007 2006

Revenues 40,790 16,970 53,349 23,452

Net profit/(loss) 27,094 5,618 5,009 (16,143)

Net operating cash flow 69,268 10,032 41,686 (7,979)
Cash and marketable securities,
end of period 287,571 94,421 287,571 94,421

For the complete report please see www.intercell.com

Further inquiry note:
Lucia Malfent
Head of Corporate Communications
Campus Vienna Biocenter 2, A-1030 Vienna
P: +43-1-20620-303
Mail to: [email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes:
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print